Results of the SIOP 93-01/GPOH Trial and Study for the Treatment of Patients with Unilateral Nonmetastatic Wilms Tumor

Abstract

Patients with unilateral Wilms tumor without metastasis have an excellent prognosis. The post-operative chemotherapy in stage I can be reduced to 4 weeks without worsening treatment outcome. The reduction of the tumor volume could be identified as a helpful marker for stratification of post-operative treatment. Post-chemotherapy blastemal predominant subtype of Wilms tumor has to be classified as high risk tumor. Focal anaplasia has a better prognosis than diffuse anaplasia and will be classified as intermediate risk tumor.

Neoadjuvant Transcatheter Arterial Chemoembolization and Systemic Chemotherapy for the Treatment of Wilms Tumor

“…The SIOP studies largely focus on the issue of preoperative chemotherapy to facilitate surgery of a shrunken tumor and to treat metastasis as early as possible. The duration of conventional preoperative chemotherapy is 4 or 8 weeks (2,(36)(37)(38). Preoperative chemotherapy is also used for the treatment of "inoperable" or "unresectable" Wilms tumor by NWTS and United Kingdom Children's Cancer Study group in recent years (39,40).…”

Tamanho tumoral e prognóstico em pacientes portadores de tumor de Wilms

“…For the tumor volume, the patients were classified according to the reduction between the TVBPQ and TVAPQ in: (1) poor response (<40%) and (2) good response (≥40%). 10 We also evaluated whether patients with TVAPQ greater than 500mL had a poorer prognosis, as Reinhard et al 11 suggested.…”

“…Furthermore, the influence of tumor response to adjuvant chemotherapy in terms of reducing its volume has been studied, as demonstrated in the studies SIOP 9/German Society of Pediatric Oncology and Hematology (GPOH) 9 , 10 and SIOP 93-01/GPOH. 11 They raise the possibility that the reduction of tumor volume, besides the classification of histological types of risk, could serve as a new prognostic parameter for the stratification of patients at the time of postoperative treatment. Therefore, currently only GPOH uses tumor volume as a parameter for risk stratification.…”

Congenital mesoblastic nephroma. Own experience of the Research Institute of Pediatric Oncology and Hematology of N.N. Blokhin National Medical Research Centre of Oncology, Ministry of Health of Russia

“…Однако через 6 мес после оперативного лечения при контрольном обследовании по данным УЗИ ОБП в ложе удаленной левой почки визуализировалось гипоэхогенное образование размерами 50 × 44 × 33 мм (объем -37,8 см 3 Обсуждение ВМН -редкая первичная опухоль почки у детей раннего возраста, характеризующаяся промежуточным биологическим поведением [3,4]. На долю ВМН приходится 3 % всех случаев опухолей почек у детей [3][4][5]. В литературе не имеется описаний с двусторонним поражением почек при ВМН, в отличие от опухоли Вильмса.…”

“…Врожденная мезобластная нефрома (ВМН) -редкое ЗНО, составляющее 3 % всех новообразований почек у детей [3,4]. ВМН наиболее распространенная опухоль почки у детей первых 6 месяцев жизни [4,5].…”